<DOC>
	<DOCNO>NCT00987766</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine hydrochloride oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . Erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth . Giving gemcitabine hydrochloride oxaliplatin together erlotinib hydrochloride may kill tumor cell . PURPOSE : This phase I trial study side effect best dose erlotinib hydrochloride give together gemcitabine hydrochloride oxaliplatin treat patient advanced biliary tract cancer , pancreatic cancer , duodenal cancer , ampullary cancer .</brief_summary>
	<brief_title>Gemcitabine Hydrochloride , Oxaliplatin , Erlotinib Hydrochloride Treating Patients With Advanced Biliary Tract Cancer , Pancreatic Cancer , Duodenal Cancer , Ampullary Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose recommend phase II dose erlotinib hydrochloride combination gemcitabine hydrochloride oxaliplatin patient advanced biliary tract cancer , pancreatic cancer , duodenal cancer , ampullary cancer . Secondary - To describe antitumor activity associate treatment regimen give dose-escalation expanded-cohort portion study . - To evaluate e-cadherin , vimentin , fibronectin , amphiregulin , Kras status tumor assess relationship response . OUTLINE : This multicenter , dose-escalation study erlotinib hydrochloride . Patients receive gemcitabine hydrochloride IV day 1 , oxaliplatin IV 2 hour day 2 , oral erlotinib hydrochloride daily day 3-8 . Courses repeat every 2 week absence disease progression unacceptable toxicity . Tumor tissue sample collect biomarker analysis . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Only advanced carcinoma define unresectable metastatic histologically cytologically confirm biliary tract , pancreas , duodenal , ampullary carcinoma include . Doseescalation : Patients &gt; 18 year age biopsyconfirmed advanced biliary tract adenocarcinoma , pancreas cancer , duodenal cancer , ampullary cancer MTD expansion cohort : Patients &gt; 18 year age biopsyconfirmed advanced biliary tract adenocarcinoma . No prior chemotherapy prior EGF receptor inhibitor therapy Measurable tumor image examination Performance status ( PS ) 02 ECOG performance scale Have pretreatment bilirubin &lt; 2.5x upper limit normal ( ULN ) , serum creatinine &lt; 1.5x ULN , AST ALT &lt; 2.5xULN presence liver metastasis &lt; 5xULN , neutrophil &gt; 1500 , platelets &gt; 100K , hemoglobin &gt; 9 g/dL Patients male female reproductive potential ( ie , menopausal less 1 year surgically sterilize ) must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior registration . Have ability understand requirement study provide inform consent CNS metastases Uncontrolled infection Pregnant nursing woman may participate . No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree 5 year . Psychiatric illness would prevent understanding nature investigational therapy comply protocol requirement Patients &gt; grade 2 neuropathy Patients &gt; grade 2 uncontrolled nausea vomit despite antiemetic Any concurrent medical condition , judgment investigator , would make patient inappropriate candidate study enrollment Prior chemotherapy EGFR inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>periampullary adenocarcinoma</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>adenocarcinoma extrahepatic bile duct</keyword>
	<keyword>adenocarcinoma gallbladder</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
</DOC>